Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Tolerance and chimerism.

Hans-Jochem Kolb1, Wolfgang Guenther, Boglarka Gyurkocza

  • 1Clinical Cooperative Group Haematopoietic Cell Transplantation, Department of Medicine III, University of Munich, Grosshadern, Munich, Germany. kolb@med3.med.uni-muenchen.de

Transplantation
|June 24, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Daratumumab therapy for refractory immune cytopenias after allogeneic hematopoietic cell transplantation.

Bone marrow transplantation·2026
Same author

Cytotoxic CD39<sup>+</sup> tumor-associated NK cells respond to NKG2A blockade in lung cancer.

Science immunology·2026
Same author

The pleuroparenchymal fibroelastosis atlas reveals aberrant cell states and their zonation as an alternate roadmap to lung fibrosis.

Science advances·2026
Same author

Probiotic-conditioned microbiota from preterm infants modulate immune response to pathogen challenge in a microbiota-humanized mouse model.

Frontiers in immunology·2026
Same author

The Impact of Post-Transplant Interventions and Chronic GVHD on Survival in Myeloid Malignancies Harboring TP53 Alterations.

Transplantation and cellular therapy·2026
Same author

Prophylactic Donor Lymphocyte Infusions in Pediatric Patients With High-Risk Hematological Malignancies.

European journal of haematology·2026
Same journal

Preformed Anti-DQ Alpha Donor-specific Antibodies and the Risk of Antibody-mediated Rejection After Kidney Transplantation.

Transplantation·2026
Same journal

People in Transplantation: Professor Nadey Hakim, MD, PhD, FRCS, FRCSGlas (Hon), FACS, President-Elect of The Transplantation Society.

Transplantation·2026
Same journal

IL-1 Receptor Blockade Modulates Inflammation During Sequential Perfusion in Ex Vivo Porcine Kidneys.

Transplantation·2026
Same journal

Regulatory T Cells Allosensitized Under the Blockade of CD80/CD86-CD28 Costimulation Prolonged Islet Allograft Survival.

Transplantation·2026
Same journal

Desensitization With Tocilizumab and IVIg: A Prospective Controlled Cohort Study in a Predominantly Black American Population.

Transplantation·2026
Same journal

From Preservation to Repair: Clinical and Ethical Implications of Organ Reconditioning in the era of Machine Perfusion.

Transplantation·2026
See all related articles

Haploidentical stem cell transplants are now successful for aggressive cancers. New protocols using cyclophosphamide, irradiation, and T-cell depletion, plus CD6-depleted mobilized donor blood cells, reduce rejection and graft-versus-host disease.

Area of Science:

  • Hematology
  • Immunology
  • Transplantation Medicine

Background:

  • Haploidentical stem cell transplants face high rejection and graft-versus-host disease (GVHD) risks when HLA mismatches exceed one.
  • Previous protocols struggled with significant complications in treating aggressive hematologic neoplasia.

Purpose of the Study:

  • To develop and evaluate novel treatment protocols for successful HLA-haploidentical stem cell transplantation.
  • To mitigate risks of rejection and GVHD in patients with high-risk hematologic malignancies.

Main Methods:

  • Utilized cyclophosphamide and total-body irradiation for conditioning regimens.
  • Employed T-cell depletion strategies to prevent GVHD.
  • Introduced CD6-depleted mobilized donor blood cells (MDBC) combined with marrow for enhanced immunomodulation.

Related Experiment Videos

Main Results:

  • Demonstrated successful treatment of 36 patients with aggressive hematologic neoplasia.
  • Achieved significant reduction in rejection and GVHD incidence.
  • Showcased the efficacy of CD6-depleted MDBC in providing immunoregulatory cells.

Conclusions:

  • HLA-haploidentical stem cell transplantation is a viable and successful option for high-risk hematologic neoplasia.
  • Encourages earlier application of this transplantation method.
  • Suggests potential applications for tolerance induction in organ transplantation.